Another use for Avastin… blebs!

Article

Bevacizumab (Avastin) may have an application as an adjunct to antifibrosis therapy, according to study results published in the October/November issue of the Journal of Glaucoma.

Bevacizumab (Avastin) may have an application as an adjunct to antifibrosis therapy, according to study results published in the October/November issue of the Journal of Glaucoma.

Michael A. Coote, MBBS, FRANZCO of the University of Melbourne, Australia and colleagues administered a subconjunctival injection of bevacizumab to a bleb. The team monitored bleb vascularity and measured any longitudinal changes that occurred in the six months prior to, and for the six months following, the bevacizumab injection.

Three months after one eye underwent trabeculectomy, cataract surgery was required; 10 days postoperatively, increased scarring activity was correlated to bleb vascularity. The researchers found that the single subconjunctival injection of bevacizumab was associated with a significant reduction in bleb vascularity for six weeks and, at six months, with additional continued steroid therapy, the bleb functioned well, had minimal scar tissue and was healthy and diffuse.

Because the bleb responded so well to the bevacizumab injection, the researchers concluded that this treatment may provide an effective adjunct to antifibrosis therapy, although further studies into bevacizumab’s effect on bleb scarring activity are required.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.